



November 1st, 2021

Whiz Partners Inc.

Whiz Partners Established a New Company to Generate Composition of Matter Patents for New Chemical Entities and Contribute to the R&D of Pharmaceutical Companies

Whiz Partners Inc. (Minato-ku Tokyo, Japan, Atsushi Matsumura President & CEO, hereinafter “Whiz Partners”) established IP Generator Inc. (Minato-ku, Tokyo, Japan, Satoru Iino, President & CEO, hereinafter "IPG") as a wholly owned subsidiary of the Healthcare New Platform Fund Limited Partnership, where Whiz Partners has been the general partner. IPG will generate composition of matter patents for new chemical entities by conducting non-clinical research and development activities and make variety of transactions mainly with pharmaceutical companies.

IPG will enter into a comprehensive business alliance with Axcelead and its subsidiary Axcelead Drug Discovery Partners (hereinafter "ADDP"), where ADDP has taken over about 200 promising drug seeds inherited from Takeda Pharmaceutical Company Limited (hereinafter “Takeda”). IPG will prioritize and select non-clinical research projects from ADDP’s promising drug seeds and a wide range of pharmaceutical companies and conduct non-clinical research activities by itself. Then, IPG will acquire composition of matter patents for new chemical entities and license out them to pharmaceutical companies. Utilizing IPG may lead pharmaceutical companies to be able to continuously replenish their R&D pipelines and accelerate the horizontal division of labor model, which is expected to have a significant positive impact on the efficiency of R&D activities. There is no capital relationship between IPG and the Axcelead Group.

In the pharmaceutical industry, we believe that the number of companies promoting business based on the concept of personalized medicine will increase in the future. As a result, IPG will become a new platform company in the pharmaceutical industry, as it enables the efficient creation of a large number of new drug candidates and the penetration of R&D strategies aimed at delivering small quantities of a wide variety of drugs to people in line with their individual needs. We believe that the ecosystem promoted by IPG will become a system that contributes to society by reducing healthcare costs in many countries.

【Outline of the company】

Name of the Company	IP Generator Inc.
Location	2-5-1 Atago, Minato-ku, Tokyo 105-6236
Investor	Healthcare New Platform Fund (100%) General Partner; Whiz Partners Inc.



Capital and Capital Reserves	10 million JPY
Established	October 26 th , 2021
Business Scope	(1) R&D and sales of pharmaceuticals (2) Business in increasing the value of intellectual property and selling usage rights (3) All other businesses incidental and related to the above
Management	President CEO Satoru Iino Board of directors Tatsuya Yamada Board of directors Yuki Hasegawa Auditor Takashi Yamaguchi

About Whiz Partners Inc.

Whiz Partners Inc. (Tokyo, Japan) is an alternative asset management firm with Growth Equity and Global Macro Hedge fund offerings. Whiz Partners has a strong track record, not only in Healthcare investments but also in information technology and AI. For more information about Whiz Partners, please visit their website <http://www.whizp.com/e/>

About Healthcare New Platform Fund

Healthcare New Platform Fund is planning to invest mainly in new healthcare platform companies, such as “Axcelead, Inc.”, the first healthcare platform company in Japan, and CDMO company “ARCALIS, Inc.” which will build a Japan’s first and only plant of APIs and formulations for mRNA drugs and vaccines in Minami-soma, Fukushima. For further information, please refer to the press release (http://www.whizp.com/wp-content/uploads/2021/10/1906_01.pdf)

Contact: Eri Yokota yokota@whizp.com